Combination Treatment with Apricoxib and IL-27 Enhances Inhibition of Epithelial-Mesenchymal Transition in Human Lung Cancer Cells through a STAT1 Dominant Pathway

BACKGROUND: The cyclooxygenase 2 (COX-2) pathway has been implicated in the molecular pathogenesis of many malignancies, including lung cancer. Apricoxib, a selective COX-2 inhibitor, has been described to inhibit epithelial-mesenchymal transition (EMT) in human malignancies. The mechanism by which...

Full description

Saved in:
Bibliographic Details
Published in:J Cancer Sci Ther
Main Authors: Lee, Mi-Heon, Kachroo, Puja, Pagano, Paul C, Yanagawa, Jane, Wang, Gerald, Walser, Tonya C, Krysan, Kostyantyn, Sharma, Sherven, John, Maie St., Dubinett, Steven M, Lee, Jay M
Format: Artigo
Language:Inglês
Published: 2014
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4624255/
https://ncbi.nlm.nih.gov/pubmed/26523208
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4172/1948-5956.1000310
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items